Pascal, K.E., Coleman, C.M., Mujica, A.O., Kamat, V., Badithe, A., Fairhurst, J., Hunt, C., Strein, J., Berrebi, A., Sisk, J.M., Matthews, K.L., Babb, R., Chen, G., Lai, K.V., Huang, T.T., Olson, W., Yancopoulos, G.D., Stahl, N., Frieman, M.B. and Kyratsous, C.A. (2015) Pre- and Postexposure Efficacy of Fully Human Antibodies against Spike Protein in a Novel Humanized Mouse Model of MERS-CoV Infection. Proceedings of the National Academy of Sciences of the United States of America, 112, 8738-8743.
www.pnas.org/cgi/doi/10.1073/pnas.1510830112

has been cited by the following article:

• TITLE: Review on Middle East Respiratory Syndrome

  AUTHORS: Berihun Dires, Fufa Dawo

  KEYWORDS: Middle East Respiaratory Syndrome-Coronavirus, Middle East Respiratory Syndrome, Betacoronavirus, Real Time Reverse Transcription PCR, Serology

  JOURNAL NAME: Open Access Library Journal, Vol.2 No.12, December 9, 2015

  ABSTRACT: Middle East respiratory syndrome (MERS) is a respiratory disease caused by a newly recognized Middle East respiratory syndrome-coronavirus (MERS-CoV). It is an RNA virus, with positive sense, single-stranded RNA genomes of 30.1 kilobase (kb). Based on its genome sequence, the virus has been classified within lineage 2C of the genus Betacoronavirus. The disease was first reported in 2012 and is now spreading to different parts of the world. Dromedary camels (Camelus dromedarius) are suggested to be the primary animal host that acts as a source of human infection by MERS-CoV. Most patients with MERS-CoV infection have been severely ill with pneumonia and acute respiratory distress syndrome, and some showed acute kidney injury. There is no specific vaccine or treatment for MERS-CoV infection other than supportive treatment. Collection of the specimens from lower respiratory tract, upper respiratory tract and serum for isolation and characterization of the virus using different techniques such as real time reverse transcription polymerase chain reaction (RT-rt PCR) and serological tests are recommended. Up to June 18, 2015, 498 of the 1327 cases have died with case fatality rate of ~38% [1]. This emerging infectious disease is a threat to human health. Proper infection-control measures including contact and airborne precautions should be implemented while managing patients with suspected MERS-CoV infection.